Tag: Cancer: Esophageal
ChemoRT Then Immunochemotherapy Then Surgery Promising in Unresectable Esophageal Cancer
One-year progression-free survival, overall survival was 79.4, 89.6 percent; significantly longer survival seen in patients who achieved resectability
Omitting 5-FU Bolus Does Not Reduce Survival in Advanced Cancer
However, omission does result in reductions in neutropenia, thrombocytopenia, and use of granulocyte colony-stimulating factor
Blood Test Results Can Enhance Assessment of Cancer Risk
Blood test results enhance assessment of risk for patients presenting with nonspecific abdominal symptoms
Study Examines Trends in Esophageal Cancer Disparities Over Time
From 1999 to 2020, decrease seen in mortality among Black adults, while mortality stabilized among White adults
Fruquintinib + Paclitaxel Aids Advanced Gastric/Gastroesophageal Junction Cancer
Improvement seen in progression-free survival among patients who had disease progression on first-line chemotherapy
Consumption of Ultra-Processed Foods Tied to Upper Digestive Tract Cancers
Increased body fat only explained a small proportion of the association
ESMO: Pembrolizumab + Chemo, Trastuzumab Beneficial in Gastroesophageal Cancer
Improvement seen in progression-free survival with add-on pembrolizumab in gastroesophageal junction adenocarcinoma
Zolbetuximab Plus CAPOX Beneficial for Advanced mG/GEJ Adenocarcinoma
Progression-free survival and overall survival prolonged with zolbetuximab plus CAPOX versus placebo plus CAPOX
K-ECAN Tool Can Predict Esophageal, Gastric Cardia Adenocarcinoma
Screening tool was well calibrated and had better discrimination than previous models including HUNT, Kunzmann
One-Fourth of Esophageal Cancers Among Those With BE Missed in Year Before Diagnosis
Authors say there is need to improve effectiveness of screening and surveillance practices for early cancer detection in patients with Barrett esophagus
